BioSpace News Archive

The Retina Center of St. Louis County is excited to share recent data that was published in the peer-reviewed journal Ophthalmology and Therapy, titled Prevention Surpasses Treatment: 5-year Follow-Up, Cost-Utility, and Cost-Benefit of Zeaxanthin Therapy for Neovascular Age-Related Macular Degeneration.

AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has successfully developed the world’s first rapid, point-of-care, non-invasive diagnostic assay for the detection of abnormal alpha-synuclein, a known biomarker for Parkinson’s Disease (PD).

SciSparc Ltd. announced that it has engaged Rosario Capital Ltd., one of Israel’ leading investment banks, to identify potential opportunities for a strategic transaction.

Sanara MedTech Inc. announced that Zach Fleming, the Company’s Chief Executive Officer, will present at the MicroCapClub Leadership Summit in Chicago, Illinois, on Wednesday, September 20, 2023 at 1:30 p.m. CT and at the Cantor Fitzgerald Global Healthcare Conference in New York, New York on Tuesday, September 26, 2023 at 1:00 p.m. ET.

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company has received approval from the Bellberry Human Research Ethics Committee (HREC) in Australia to initiate a Phase 1 clinical study of its lead drug candidate GT-02287 in development for GBA1-Parkinson’s disease (GBA1-PD).

Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting diabetes management and personalized lifestyle coaching programs, today announced it will be participating at the HLTH 2023 conference, in Las Vegas, in October.

Stryker (NYSE: SYK), one of the world’s leading medical technology companies, announced that its Pangea Systems including Femur, Fibula, Tibia, Humerus and Utility have received 510k clearance from the U.S. Food & Drug Administration.

UroMems, a global company developing innovative, mechatronics technology to treat stress urinary incontinence, announced that it has successfully completed enrollment in its first-in-man study of the UroActive™ System, the first smart automated artificial urinary sphincter to treat SUI.

Northwest Biotherapeutics announces that Dr. Linda Liau, MD, PhD, MBA has joined the Company’s Scientific Advisory Board.

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that Board-certified hematologist and medical oncologist Raphael Bosse, MD, PhD has joined the statewide practice.